BGI (THAILAND) CO., LTD.

A Global Pioneer in Next Generation Sequencing

Biotechnology leader BGI is one of the world's largest genomics organizations, which is the science focusing on the study of the human genomes, that is increasingly being utilized as a tool to help medical practitioners better understand disease and evaluate healthcare treatment options. Originally established in 1999 as a nongovernmental research institute in order to participate in the Human Genome Project, they have since grown into an organization which currently works with more than 3000 medical institutions and more than 300 hospitals. They are headquartered in Shenzhen, China, with additional branches and medical laboratories in Beijing, Tianjin, Wuhan, Shanghai and Guangzhou. BGI also has offices and laboratories located in Europe, North America and the Asia Pacific region, operating in a total of more than 100 countries and regions. Recently they opened their first offices in Thailand. They offer a wide range of genetic testing products for many major diseases, which allow medical providers and patients to realize the benefits of genomics-based diagnostics and personalized healthcare

WHY THAILAND

Recognizing Thailand's strategic location as the gateway to the rest of Southeast Asia, BGI recently made the decision to locate its trans-omics laboratory and national offices in Bangkok, which will function as its future ASEAN business hub. With an organizational vision to provide 'omics for all', BGI intends to further its investment in Thailand, especially in the Eastern Economic Corridor of Innovation (EECi).

With assistance from the BOI, BGI has expanded its operations in Thailand to include genomics, agriculture, marine aquaculture, and forensics. In February 2018, BGI received an import certificate from the Thai Food and Drug Administration, meaning that a wide range of products can now be legally launched into the Thai market. Not only will this help to expedite the establishment of the Thai Genomics Center, but it will also be an integral part in China's 'Belt and Road Initiative' program across Asia.



VISION FOR THE FUTURE

Developing solutions for the betterment of mankind is at the heart of everything that BGI does. To further this goal, BGI is active in conducting research across the region in areas including agriculture and food science, cancer research, reproductive health and drug discovery. Since BGI Research was first established, they have gone on to work together with scores of research and academic institutions worldwide. With a proven record in research and innovation both globally and regionally, BGI is well placed to continue driving Asia's growth in the genomics sector. They are committed to working closely with both new and existing partners to further solidify their role both with in Thailand and across the region.

BGI's vision is to use genomics to benefit mankind and to achieve the goal of providing omics for all"

Mr. Duncan Yu Executive Vice President of BGI

SUPPORTING POLICIES FROM THE GOVERNMENT

Thailand's position as an international biomedical hub attracts both patients and tourists to the country. The government, in recognizing the importance of the medical sector, has allocated THB12.5 billion (USD 376.3 million) in healthcare spending. The Thai government and the BOI strongly support the efforts of Thai companies in the private sector which are looking to generate increased business opportunities in the global market.







ATTRACTIVE BOI INCENTIVES

The Thailand Board of Investment (BOI) offers a wide range of tax and non-tax incentives for projects that meet national development objectives.

Tax-based incentives include an exemption or reduction of import duties on machinery and raw materials, as well as corporate income tax exemptions of up to eight years. Non-tax incentives include permission to bring in expatriates, own land and take or remit foreign currency abroad.

Additional information about specific activities relating to the medical and healthcare industries can be found by clicking **here** or contacting the BOI's Investment Promotion Division 1.

